Skip to main content
Equibles
UTHR logo

UTHR · UNITED THERAPEUTICS Corp · Metrics

Track UTHR — free

Use UTHR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research UTHR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$587.50 +2.71 (+0.46%) At close · Oct 23
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$25.20B
Shares
42.89M
Volume · Oct 23 638.15K Avg daily vol (3M) 712.96K

UTHR metrics

115 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$587.50
Market cap
$25.20B

Price action

20 metrics
Price change (1W)
+10.2%
Price change (30D)
+23.6%
Price change (3M)
+11.2%
Price change (6M)
+3.6%
Price change (YTD)
+20.6%
Price change (1Y)
+37.8%
Trailing year
Price change (5Y)
+207.6%
52-week high
$596.76
52-week low
$415.34
Change from 52-week high
-1.6%
Change from 52-week low
+41.5%
Annualized volatility
35.6%
Annualized volatility (3M)
37.8%
Beta
0.2
RSI (14D)
69.2
Price vs SMA 50
+13.1%
Price vs SMA 200
+11.1%
Avg volume (3M)
712,964
Relative volume
0.9
Average dollar volume
$372.95M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
42.89M

Valuation

12 metrics
P / E (TTM)
21.0
Trailing earnings · reciprocal yield 4.8%
PEG ratio
1.6
EV / revenue
7.1×
reciprocal yield 14.0%
EV / EBITDA
15.1×
reciprocal yield 6.6%
EV / EBIT
16.1×
reciprocal yield 6.2%
P / sales
8.0×
reciprocal yield 12.5%
P / book
3.9
reciprocal yield 25.4%
FCF yield
4.3%
TTM · current market cap
Buyback yield
9.9%
P / FCF
23.1
reciprocal yield 4.3%
P / operating cash flow
15.0
reciprocal yield 6.7%
Earnings yield
5.2%

Historical valuation

8 metrics
P / E historical average (3Y)
15.1×
reciprocal yield 6.6%
P / E historical average (5Y)
15.1×
reciprocal yield 6.6%
EV / revenue historical average (3Y)
5.3×
reciprocal yield 18.7%
EV / revenue historical average (5Y)
5.3×
reciprocal yield 18.7%
EV / EBIT historical average (3Y)
11.6×
reciprocal yield 8.6%
EV / EBIT historical average (5Y)
11.6×
reciprocal yield 8.6%
EV / EBITDA historical average (3Y)
10.5×
reciprocal yield 9.5%
EV / EBITDA historical average (5Y)
10.5×
reciprocal yield 9.5%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
9.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-04
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
86.1%
Operating margin
44.4%
Trailing 12 months
Net margin
41.6%
Gross profit (TTM)
$2.72B
Operating profit (TTM)
$1.40B
Net income (TTM)
$1.31B
Trailing 12 months
Diluted EPS (TTM)
$27.91
FCF margin
34.6%
Effective tax rate
16.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$67.23
Gross profit per diluted share (TTM)
$57.91
Operating profit per diluted share (TTM)
$29.86
EBITDA per diluted share (TTM)
$31.81
Net income per diluted share (TTM)
$27.94
Operating cash flow per diluted share (TTM)
$35.85
Free cash flow per diluted share (TTM)
$23.26
Capital expenditures per diluted share (TTM)
$12.59
R&D per diluted share (TTM)
$11.76
Stock compensation per diluted share (TTM)
$3.31
Book value per share
$162.60

Growth

11 metrics
Revenue growth YoY
-1.9%
Year over year
Net income growth YoY
+7.6%
Revenue (TTM)
$3.15B
Trailing 12 months
EPS growth YoY
+13.4%
Shares change YoY
-5.2%
Year over year · fewer shares
Revenue CAGR (3Y)
+18.0%
Revenue CAGR (5Y)
+16.5%
EPS CAGR (3Y)
+22.9%
EPS CAGR (5Y)
+19.3%
FCF CAGR (3Y)
+16.2%
FCF CAGR (5Y)
+8.4%

Quality

14 metrics
Return on equity
20.5%
Return on assets
18.2%
Debt / equity
0.0
Current ratio
5.7
EBITDA (TTM)
$1.49B
Free cash flow (TTM)
$1.09B
Quick ratio
5.4
Interest coverage
116.8
Net debt / EBITDA
-1.8
Return on invested capital
31.3%
Trailing 12 months
Net cash
$2.66B
Latest balance sheet
Cash & equivalents
$1.80B
Total assets
$7.22B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.69B
Capital expenditures (TTM)
$592.20M
R&D (TTM)
$551.50M
SG&A (TTM)
$764.00M
Stock compensation (TTM)
$155.40M
R&D / revenue
17.5%
Stock compensation / revenue
4.9%

Ownership (13F)

9 metrics
13F filers
888
13F filer change QoQ
+25
Institutional ownership
102.0%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
30.4%
Private-fund adviser ownership
27.9%
Active holders' share change QoQ
-1.0%
Holder tenure
16.6
Price vs estimated holder cost
+45.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
23.3%

Short interest

3 metrics
Short interest
8.4%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$331.02M
Insider-sentiment score
55 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1082554 CUSIP 91307C102 13F (30d) 182 filings 168 filers Visit website Investor relations